Spectrum Pharmaceuticals Inc expected to post a loss of 21  cents a share - Earnings Preview

Spectrum Pharmaceuticals

15/03/2022 21:00

* Spectrum Pharmaceuticals Inc  SPPI.OQ   SPPI.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 17. 
    * ​Refinitiv's mean analyst estimate for Spectrum
Pharmaceuticals
Inc is for a loss of 21 cents per share. For the same quarter
last year, the company reported a loss of 29 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spectrum
Pharmaceuticals Inc is $6​, above​ its last closing price
of $0.71. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.28       -0.28      -0.21     Beat    25
 Jun. 30 2021  -0.25       -0.25      -0.32     Missed  -25.5
 Mar. 31 2021  -0.30       -0.31      -0.25     Beat    20.6​
 Dec. 31 2020              -0.29      -0.29     Met     0
 ​​Sep.        -0.35       -0.35      -0.37     Missed  -5.7
 30 2020                                                
 Jun. 30 2020  -0.29       -0.32      -0.28     Beat    11.4​
 Mar. 31 2020  -0.34       -0.35      -0.36     Missed  -4
 Dec. 31 2019  -0.33       -0.33      -0.35     Missed  -7.4
 This summary was machine generated March 15 at 21:00 GMT.  All
figures in US dollars  unless otherwise stated